To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
Referred to the House Committee on Energy and Commerce.
Email me when HR 1843 moves
Committee action, floor votes, amendments and hearings. Free, no card, no password.
Already have an account? Track HR 1843. By continuing you agree to the Terms and Privacy Policy.
Legislative status
- Introduced
- In Committee
- Reported by Committee
- Floor Vote Scheduled
- Passed One Chamber
- Passed Both Chambers
- Sent to Executive
- Signed into Law
Summary
This bill requires the Food and Drug Administration (FDA) to inform generic drug applicants, upon request or during review, whether the drug is qualitatively and quantitatively the same as the listed brand-name drug (and if not, the reasons why). The FDA must also update or publish guidance on how it makes such determinations.
AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.
Ask about HR 1843
3 free questions a day, no accountHearings
- Markup of Seven BillsHouse Energy and Commerce · Sep 17, 2025
History
- Referred to the House Committee on Energy and Commerce.
- Introduced in House
Sponsors
- Rep. Dunn, Neal P. [R-FL-2] (R) · sponsor
- Rep. Mullin, Kevin [D-CA-15] (D)
Similar bills in other states
Loading the map of where bills like this one were filed.
Topics
Share
Writing about this bill? Add a live status widget to your site or newsletter. It updates as the bill moves.
Track this bill
Get an email when HR 1843 moves: committee action, floor votes, amendments and hearings. Free, no card.
Track HR 1843 freeOr ask your AI assistant about HR 1843 directly:
Add to Claude, ChatGPT or Cursor